FOXA1/EZH2 Ratio as a Universal Breast Cancer Subtype Classifier and Treatment Predictor: Computational Validation Across ~7,500 Patients in Seven Independent Datasets

The ratio of two standard pathology proteins — FOXA1 divided by EZH2 — was derived from first principles using Waddington landscape attractor geometry applied to 19,542 single cancer cells from 26 patients (GSE176078, Wu et al. 2021, Nature Genetics). FOXA1 is the pioneer transcription factor that opens and maintains luminal breast cell identity. EZH2 is the Polycomb repressor (PRC2 catalytic subunit) that silences that same identity programme. Their ratio measures the balance between identity maintenance and identity suppression — the biological axis that determines both breast cancer subtype and treatment sensitivity. The ordering prediction (Luminal A > Luminal B > HER2-enriched > TNBC > Claudin-low) was locked before any confirmatory analysis was performed. Across four computational scripts run against seven independent datasets comprising approximately 7,500 patients on four measurement platforms (single-cell RNA-seq, bulk microarray, bulk RNA-seq RSEM, and iTRAQ mass spectrometry proteomics), the following was established: (1) the ratio correctly orders all major subtypes in four independent datasets (p = 2.87×10⁻¹⁰³ in TCGA-BRCA, n=837; p = 8.47×10⁻⁶⁷ for LumA vs LumB in METABRIC, n=1,980); (2) AUC = 0.828–0.901 for LumA vs Basal/TNBC classification replicated independently in METABRIC and TCGA PanCancer Atlas; (3) AUC = 0.796–0.873 for LumA vs LumB replicated in both cohorts; (4) overall survival confirmed in four independent analyses totalling ~7,500 patient-observations; (5) chemotherapy resistance predicted in GSE25066 (n=508, p